简介：

简介：

简介：

简介：

简介：

简介：

简介：

简介：Objective:Toinvestigatetherelationshipbetweengenemutationandpathologicaltypeoflungcancer,inspectandverifytheconsistencybetweenhomologousgenesmutationinvariouspathologictype.Methods:CombinedwiththeCOSMICandUniProtdatabase,weobtainedthereportedoverallbig-samplemutationdataoflungcancerandtheproteinsequencesofthetop20mutatedgenes,respectively.Analyzethedataandclustertheproteinsequencesandthendeducethehomologousgene.Ultimately,analyzethemutationsofdifferentpathologicaltypesofhomologousgenes.Results:TP53(32.32%)hasthehighestmutationrateinlungcancer,followedbyEGFR(29.12%).Thecopynumbervariability(CNV)ofgenes:KRAS,LRP1B,CDKN2A,KMT2C,FAT1,PIK3CA,RB1,ERBB4,GRIN2AandKDRbetweeneachpathologicaltypeisstaticallysignificant(P<0.05).ThegenedifferentialexpressionratebetweenadenocarcinomaandsquamouscarcinomaofgeneTP53,KRAS,LRP1B,CDKN2A,STK11,FAT4,KMT2D,NFE2L2,KEAP1,PIK3CA,RB1,ERBB4,SMARCA4andKDRarestatisticallysignificant(P<0.05).ThesimilarityoftheproteinsequenceofEGFRandERBB4canreach93%,andFAT4andFAT1are81%.Forsmallcellcarcinoma,there’snodifferenceinCNVbetweenthetwogroupsofhomologousgenes,andnodifferencebetweenFAT4andFAT1inadenocarcinoma.Conclusion:TheCNVandgeneexpressionoflungcancer-associatedgenesarerelevanttopathologictypes.GFRandERBB4arehomologous,FAT4andFAT1arealsoamongthetop20mutationgenes.Additionally,there’snodifferenceinCNVbetweenthetwogroupsofsmallcellcarcinoma,whichisthesamebetweenFAT4andFAT1inadenocarcinoma.

简介：Objective:ToanalyzetheincidenceandmortalityratesoflungcancerinChinafrom2008to2012.Methods:IncidentanddeathcasesoflungcancerwereretrievedfromtheNationalCentralCancerRegistry(NCCR)databasecollectingfrom135cancerregistriesinChinaduring2008-2012.Thecrudeincidenceandmortalityratesoflungcancerwerecalculatedbyarea(urban/rural),region(eastern,middle,western),genderandagegroup(0,1-4,5-9,…,85+).Chinacensusin2000andSegi’sworldpopulationwereappliedforagestandardizedrates.JoinPoint(Version4.5.0.1)modelwasusedfortimetrendanalysis.Results:Thecrudeincidencerateoflungcancerwas54.66/100,000whichrankedthefirstinoverallcancers.Theage-standardizedincidenceratesbyChinapopulation(ASIRC)andbyWorldpopulation(ASIRW)were35.13/100,000and34.86/100,000,respectively.ThecrudemortalityoflungcancerinChinawas45.60/100,000anditwasthefirstcauseofcancer-relateddeathinoverallcancers.Theage-standardizedmortalityratesbyChinesestandardpopulation(ASMRC)andbyworldstandardpopulation(ASMRW)were28.57/100,000and28.22/100,000,respectively.Incidenceandmortalityratesoflungcancerwerehigherinmalesthaninfemalesandhigherinurbanareasthaninruralareas.Easternareashadthehighestincidenceandmortalityratesfollowedbymiddleandwesternareas.Incidenceandmortalityratesoflungcancerretainedlowlevelinagegroupsbefore40yearsoldbutincreasedgreatlyafterandpeakedinagegroupof80-84.During2003-2012,thetemporaltrendoftheincidencerateoflungcancerinbothsexesinChinawasgeneralstable(P<0.05).Thelungcancerincidencerateincreasedby0.71%peryearinfemales(P<0.05)and2.26%peryearinruralareas(P<0.05).Themortalityrateoflungcancerdecreasedslightlyannuallyduring2003-2012inChina(P>0.05).Inurbanareas,itdeclinedby0.76%peryear(P<0.05),butroseby2.09%peryear(P<0.05)inruralareas.Conclusions:Appropriatetargetedprevention,earlydetectionandtreatment

简介：Objective:LivercancerisoneofthemostcommoncancersandmajorcauseofcancerdeathsinChina,whichaccountsforover50%ofnewcasesanddeathsworldwide.Thesystematiclivercancerstatisticsincludingofprojectionthrough2030couldprovidevaluableinformationforpreventionandcontrolstrategiesinChina,andexperienceforothercountries.Methods:TheburdenoflivercancerinChinain2014wasestimatedusing339cancerregistries’dataselectedfromChineseNationalCancerCenter(NCC).Incidentcasesof22cancerregistrieswereappliedfortemporaltrendsfrom2000to2014.Theburdenoflivercancerthrough2030wasprojectedusingage-period-cohortmodel.Results:About364,800newcasesoflivercancer(268,900malesand95,900females)occurredinChina,andabout318,800livercancerdeaths(233,500malesand85,300females)in2014.WesternregionsofChinahadthehighestincidenceandmortalityrates.Incidenceandmortalityratesdecreasedbyabout2.3%and2.6%peryearduringtheperiodof2000-2014,respectively,andwoulddecreasebymorethan44%between2014and2030inChina.Theyounggeneration,particularlyforthoseagedunder40years,showedafasterdowntrend.Conclusions:Basedontheanalysis,incidenceandmortalityratesoflivercancerareexpectedtodecreasethrough2030,buttheburdenoflivercancerisstillseriousinChina,especiallyinruralandwesternareas.MostcasesoflivercancerinChinacanbepreventedthroughvaccinationandmorepreventioneffortsshouldbefocusedonhighriskgroups.

简介：

简介：

简介：

简介：肿瘤坏死因素相关的导致apoptosisligand(小道)是为anticancer的一个有希望的代理人治疗。能建立前列腺癌症(PCa)的敏感的小分子的鉴定房间到导致小道的apoptosis为PCa的指向的治疗是关键的。PC3，DU145，JAC-1，TsuPr1，和LNCaP房间与Andrographolide(Andro)被对待，小道，和apoptosis用AnnexinV/PI被测量两倍染色的方法。真实时间聚合酶链反应(PCR)和西方的污点分析被执行测量目标分子的表示层次。RNA干扰技术习惯于下面调整目标蛋白质的表示。我们建立了PCa的一个裸体老鼠异种皮移植模特儿，它被用来用流动cytometry在肿瘤房间测量caspase-3活动。在这研究研究，我们的结果证明Andro优先地在subtoxic集中增加了PCa房间的敏感到导致小道的apoptosis，并且规定机制与DR4的起来规定有关。另外，它也增加了p53表示并且在细胞导致了反应的氧种类(ROS)的产生。进一步的研究表明DR4抑制，p53表示，和ROS产生罐头显著地减少小道和Andro的联合在PCa房间导致的apoptosis。在结论，Andro通过ROS的产生和p53的起来规定增加PCa房间的敏感到导致小道的apoptosis然后支持与DR4的激活联系的PCa房间apoptosis。

简介：

简介：

简介：Inrecentyears,theclinicalincidenceofthyroidcancerhasbeenincreasingyearbyyear,anditsriskassessmentandclinicalmanagementmethodshavealsobeenaccordinglymodifiedandconstantlyimproved.TherearegreatdifferencesbetweentheclinicaldiagnosticandtherapeuticmodesanddiseasemanagementofthyroidcanceremployedbyvariousmedicalinstitutionsinChina,particularlywithregardtotheclinicalapplicationofserummarkerofthyroidcancer.Tothisend,theChinaAnti-CancerAssociationThyroidCancerSpecializedCommitteeChineseAssociationofThyroidOncologyorganizedthiscompilationofExpertConsensusonClinicalApplicationofSerumMarkerofThyroidCancertohelpandimpelrelevantclinicalinstitutionsandprofessionalstostandardizeclinicaldiagnosis,treatment,andlong-termmanagementofthyroidcancer,andtoproperlyutilizetheserummarkerforscientificauxiliaryclinicaldiagnosisandassessmentofthyroidcancerbeforeandafteroperation.

简介：

简介：Ovariancanceristhesecondmostlethalgynecologicalcancerworldwideandwhilemostpatientsrespondtoinitialtherapy,theyoftenrelapsewithresistantdisease.Humanepidermalgrowthfactorreceptors(especiallyHER1/EGFRandHER2/ERBB2)areinvolvedindiseaseprogression;hence,strategiestoinhibittheiractioncouldproveadvantageousinovariancancerpatients,especiallyinpatientsresistanttofirstlinetherapy.Monoclonalantibodiesandtyrosinekinaseinhibitorsaretwoclassesofdrugsthatactonthesereceptors.Theyhavedemonstratedvaluableantitumoractivityinmultiplecancersandtheirpossibleuseinovariancancercontinuestobestudied.Inthisreview,wediscussthehumanepidermalgrowthfactorreceptorfamily;reviewemergingclinicalstudiesonmonoclonalantibodiesandtyrosinekinaseinhibitorstargetingthesereceptorsinovariancancerpatients;andproposefutureresearchpossibilitiesinthisarea.

简介：(PGAM1)Phosphoglycerate变位酶1是在许多癌症类型的upregulated并且在房间增长，移植，侵略，和apoptosis包含。然而，在PGAM1和前列腺癌症之间的关系糟糕被理解。现在的学习与正常前列腺纸巾相比在前列腺癌症纸巾在PGAM1表示调查了变化并且检验了有clinicopathological变量的PGAM1和它的关系的细胞的函数。Immunohistochemistry并且西方的弄污表明那PGAM1表情是在前列腺癌症纸巾和房间线的upregulated。PGAM1表示与格利森分数被联系(P=0.01)并且T阶段(P=0.009)。由在PC-3和22Rv1前列腺癌症房间线的siRNA的PGAM1击倒禁止的房间增长，移植，和侵略和提高的癌症房间apoptosis。在一个裸体老鼠异种皮移植模特儿，PGAM1击倒的显著地压制的肿瘤生长。PGAM1的删除导致了MMP-2的Bcl-2，Bax的提高的表示，caspases-3和抑制的减少的表示和MMP-9表示。我们的结果显示PGAM1可以在前列腺癌症前进和攻击性起一个重要作用，并且它可能为前列腺癌症是差的预后和一个潜在的治疗学的目标的一个珍贵标记。